NanoViricides reports animal safety data on broad-spectrum anti-coronavirus drug candidate NV-CoV-2 Feb. 11, 2021
Ad5-nCoV vaccine meets prespecified primary safety and efficacy criteria for phase III study Feb. 9, 2021
Positive phase II data for VERU-111 in hospitalized COVID-19 patients at high risk for ARDS Feb. 9, 2021
RSS